financetom
Business
financetom
/
Business
/
Nvidia's Rising Purchase Commitments, Supply Obligations Indicate Future Growth, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia's Rising Purchase Commitments, Supply Obligations Indicate Future Growth, UBS Says
Sep 1, 2024 8:25 PM

12:33 PM EDT, 08/29/2024 (MT Newswires) -- Nvidia's ( NVDA ) purchase commitments and supply obligations showed significant growth for the first time in several quarters during fiscal Q2, UBS said in a note Thursday.

Analysts, including Timothy Arcuri, said one of the key positive takeaways is the roughly $10 billion increase in the company's total supply. This includes $6.7 billion in inventory and $27.8 billion in purchase commitments. This represents a 40% increase from the previous quarter, reversing a trend of slower growth. Compared to Nvidia's ( NVDA ) revenue guidance, the ratio of supply to revenue has increased significantly. This ratio has historically been a good predictor of future revenue growth.

"Nvidia ( NVDA ) traded down in immediate post-market trading related in part to somewhat frothy expectations around where guidance would land and what we long considered be unrealistic expectations the company had set three months ago around the timing for Blackwell volume shipments and how much revenue it would see this year," the analysts said.

Starting in January, the new Blackwell product will be added on top of the existing Hopper product, which is expected to grow from the previous quarter, the analysts said, adding they are not worried about changes in gross margins, as data center margins should remain steady during the Blackwell cycle, just as they did with Hopper.

UBS maintained a buy rating and a $150 price target on Nvidia ( NVDA ).

Price: 121.29, Change: -4.33, Percent Change: -3.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Goliath Resources Provides Latest High-Grade Intersections at Surebet Discovery in British Columbia
Goliath Resources Provides Latest High-Grade Intersections at Surebet Discovery in British Columbia
Mar 11, 2026
07:57 AM EST, 01/20/2026 (MT Newswires) -- Goliath Resources ( GOTRF ) reported Tuesday the latest high-grade intersections from the 2025 drill campaign at the Surebet discovery within its Golddigger property in British Columbia. Assays include 19.13 grams per ton gold over 6.10 meters and 10.58 g/t gold over 8.30 m. The company said its drilling significantly expanded the extent...
D.R. Horton beats quarterly estimates as incentives boost home sales
D.R. Horton beats quarterly estimates as incentives boost home sales
Mar 11, 2026
Jan 20 (Reuters) - U.S. homebuilder D.R. Horton ( DHI ) posted first-quarter profit and revenue above Wall Street's estimates on Tuesday, as its incentive offers for buyers and the Federal Reserve's interest-rate cuts boosted home sales. Homebuilders in the U.S. have ‌been leaning on mortgage rate buydowns, and offering smaller and cheaper home options, to lure ​customers who have...
Market Chatter: JPMorgan, Citigroup Mull Ending Fixed Pay Allowance for Senior UK Staff
Market Chatter: JPMorgan, Citigroup Mull Ending Fixed Pay Allowance for Senior UK Staff
Mar 11, 2026
07:59 AM EST, 01/20/2026 (MT Newswires) -- JPMorgan Chase ( JPM ) and Citigroup ( C ) are considering cutting some of the fixed pay for their senior UK executives, Bloomberg reported Tuesday, citing unnamed sources having knowledge of the matter. JPMorgan ( JPM ) will decide in the coming weeks whether to pare back or scrap fixed allowances for...
Invivyd to Launch Mid-Stage Trial for Investigational Antibody on Long COVID
Invivyd to Launch Mid-Stage Trial for Investigational Antibody on Long COVID
Mar 11, 2026
07:58 AM EST, 01/20/2026 (MT Newswires) -- Invivyd ( IVVD ) said Tuesday that it plans to launch a mid-stage clinical trial, along with the SPEAR Study Group, that assesses the safety, translational biology, and exploratory clinical efficacy of investigational antibody VYD2311 in individuals with Long COVID or COVID vaccine injury. The trial will evaluate multiple high doses of the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved